Valeant Builds Outside Of Dermatology With Bausch + Lomb Buy
This article was originally published in The Rose Sheet
Acquisition of Bausch + Lomb for $8.7 billion vaults Valeant Pharmaceuticals into consumer eye care and positions the firm to compete against pharma giants. Analysts see the move as representing “a good fit,” and the acquisition is not likely to be the last for Valeant, which has made M&A an integral part of its strategy.
You may also be interested in...
Yehia Hashad joins Bausch + Lomb as R&D executive VP and chief medical officer before a planned IPO; Global Organization for EPA and DHA Omega-3s begins 2022 creating a position of growth and engagement director and adding two team members.
J&J takes same approach GSK, Pfizer, Merck & Co, Merck and Novartis have with their consumer health businesses, Bausch Health is starting and Sanofi says it will.
FDA invites public input in preparation for the seventh meeting of national authorities under the International Cooperation on Cosmetics Regulation, while The National Toxicology Program requests information on technologies and non-animal approaches that can be used to screen compounds for potential neurotoxicity. More news in brief.